Effect of physical activity on lipid levels in a population-based sample of men with and without the Arg192 variant of the human paraoxonase gene

Genetic Epidemiology

Volumn 18, Issue 3, 2000, Pages 276-286

  Sentí, Mariano ^a   Aubó, Clara ^a   Elosua, Roberto ^a   Sala, Joan ^b   Tomás, Marta ^a   Marrugat, Jaume ^a  

^a INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Genetics; Lipids; Paraoxonase; Physical activity

Indexed keywords

ARGININE; LIPID;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; ENERGY EXPENDITURE; GENE MUTATION; GENOTYPE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; POPULATION RESEARCH; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SPAIN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALLELES; ARGININE; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ESTERASES; EXERTION; HUMANS; ISOENZYMES; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0034023655     PISSN: 07410395     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2272(200003)18:3<276::AID-GEPI6>3.0.CO;2-J     Document Type: Article

References (32)

1. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen M, Frick MH, Ehnholm C. 1996. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary heart disease in Finns. J Clin Invest 98:883-885.
2. Artaud-Wild SM, Connor SL, Sexton G, Connor WE. 1993. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. Circulation 88:2771-2779.
3. Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui L-C, Hegele RA. 1998. Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma in Alberta Hutterites. Atherosclerosis 139:131-136.
4. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. 1994. Validation of the Minnesota leisure time physical activity questionnaire in Spanish men. Am J Epidemiol 139:1197-1209.
5. Erikssen G, Liestol K, Bjonholt J, Thaulow E, Sandvik L, Erikssen J. 1998. Changes in physical fitness and changes in mortality. Lancet 352:759-762.
6. Havel RJ. 1990. Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 81:694-696.
7. Regele RA, Brunt JH, Connelly PW. 1995. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 15:89-95.
8. Herrmann S-M, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, Marques-Visal P, Bard J-M, Cambien F. 1996. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 126:299-303.
9. Humbert R, Adler DA, Disteche CM, Hassett C, Omienski CJ, Furlong CE. 1993. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73-76.
10. Kuusi T, Ehnholm C, Viikari J, Harkonen R, Vartiainen E, Puska P, Taskinen HR. 1989. Postheparin plasma lipoprotein and hepatic lipase are determinants of hypo- and hyperalphalipoproteinemia. J Lipid Res 30:1117-1126.
11. Lakka TA, Venäläinen JM, Rauramaa R, Salonen R, Tuomilehto J, Salonen JT. 1994. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction. N Engl J Med 330:1549-1554.
12. Mackness MI, Arrol S, Durrington PN. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286:152-154.
13. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. 1996. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 7:69-76.
14. Marrugat J, Elosua R, Covas MI, Molina L, Rubiés-Prat J. 1996. Amount and intensity of physical activity, physical fitness, and serum lipids in men. Am J Epidemiol 143:562-569.
15. Masiá R, Pena A, Marrugat J, Sala J, Vila J, Pavesi M, Covas M, Aubó C, Elosua R. 1998. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. J Epidemiol Commun Health 52:707-715.
16. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV. 1996. Recent trends in acute coronary heart disease mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. N Engl Med J 334:884-890.
17. Miller SA, Dykes DD, Polesky HF. 1989. A simple salting-out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res16:1215.
18. Nevin DN, Zambon A, Furlong CE, Richter RJ, Humbert R, Hokanson JE, Brunzell JD. 1996. Paraoxonase genotypes, lipoprotein lipase, and HDL. Arterioscler Thromb Vasc Biol 16:1243-1249.
19. Ombres D, Panniteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G, Area M. 1998. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18:1611-1616.
20. Pekkanen J, Marti B, Nissinen A, Tuomilehto J, Punsar S, Karvonen MG. 1987. Reduction of premature mortality by high physical activity: a 20-year follow-up of middle-aged Finnish men. Lancet 1:1473-1477.
21. Pérez G, Pena A, Sala J, Roset P, Masiá R, Marrugat J. 1998. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in the province of Girona, Spain, 1990 to 1992. Int J Epidemiol 27:599-604.
22. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. 1987. Physical activity and the incidence of coronary heart disease. Annu Rev Public Health 8:253-287.
23. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. 1996. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
24. Rice GI, Ossei-Gerning N, Stickland MH, Grant PJ. 1997. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis 8:677-682.
25. Ruiz J, Blanche H, James RW, Blatter Garin M-C, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. 1995. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346:869-872.
26. Sanghera DK, Saha N, Aston CE, Kamboh MI. 1997. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 17:1067-1073.
27. Sentí M, Nogués X, Pedro-Botet J, Rubiés-Prat J, Vidal-Barraquer F. 1992. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation 85:30-36.
28. Serrato M, Marian AJ. 1995. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 96:3005-3008.
29. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamahige N, Hashimoto K. 1996. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 57:69-73.
30. Taylor HL, Jacobs Dr Jr, Schucker B, Knudsen J, Leon AS, Debacker G. 1978. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 31:741-755.
31. Weintraub M, Rosen Y, Otto R, Eisenberg S, Breslow J. 1989. Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 79:1007-1014.
32. 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 17:3565-3569.